The company said that its fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk.
・The company’s Yartemlea was approved by the U.S. Food and Drug Administration for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in December.
・The company is now looking forward to an approval for the therapy from the European Medicines Agency by mid-2026.
Shares of Omeros Corporation (OMER) rose 5% after hours on Tuesday after the company expressed optimism for its deal with Danish drugmaker Novo Nordisk and regarding its other drugs.
The company reported net income for the fourth quarter of $86.5 million, compared to a net loss of $31.4 million in the corresponding quarter of 2024.
The company said that its fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk. Under the deal valued up to $2.1 billion, the Danish drugmaker received exclusive global rights in all indications to develop and commercialize Omeros’s zaltenibart and certain related antibodies and products.
The transaction was closed in November, triggering an upfront cash payment of $240 million. The company is now eligible to receive milestone payments and tiered royalties on annual global net sales of applicable products.
Remaining Lineup
The company’s Yartemlea was approved by the U.S. Food and Drug Administration for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and in children ages two years and older in December. Commercial distribution and sales of Yartemlea in the U.S. began in January. The drug is now being prescribed to both adult and pediatric patients across both hospital and outpatient settings, the company said, while adding that it has engaged several of its workforce to engage directly with transplant centers across the United States.
The company is now looking forward to an approval for the therapy from the European Medicine Agency by mid-2026.
“Following FDA approval of Yartemlea with a broad label and no boxed warning, REMS, or required vaccinations, our commercial launch is well underway, and patients who urgently need the drug are now able to access it,” said Omeros CEO Gregory A. Demopulos. “Our partnership with Novo Nordisk expands the breadth of indications being pursued for zaltenibart and has provided — and should continue to provide — substantial operating capital... These successes are expected to fuel the development of a growing portfolio of commercial products from our robust pipeline as we target positive cash flow in 2027.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.